WO2019172598A1 - Nanovésicules dérivées de bactéries lactobacillus sp., et leur utilisation - Google Patents

Nanovésicules dérivées de bactéries lactobacillus sp., et leur utilisation Download PDF

Info

Publication number
WO2019172598A1
WO2019172598A1 PCT/KR2019/002500 KR2019002500W WO2019172598A1 WO 2019172598 A1 WO2019172598 A1 WO 2019172598A1 KR 2019002500 W KR2019002500 W KR 2019002500W WO 2019172598 A1 WO2019172598 A1 WO 2019172598A1
Authority
WO
WIPO (PCT)
Prior art keywords
lactobacillus
vesicles
lacotobacillus
derived
bacteria
Prior art date
Application number
PCT/KR2019/002500
Other languages
English (en)
Korean (ko)
Inventor
김윤근
Original Assignee
주식회사 엠디헬스케어
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190024891A external-priority patent/KR102101692B1/ko
Application filed by 주식회사 엠디헬스케어 filed Critical 주식회사 엠디헬스케어
Priority to EP19764446.1A priority Critical patent/EP3763830A4/fr
Priority to JP2020546410A priority patent/JP2021516054A/ja
Priority to US16/978,597 priority patent/US20210030821A1/en
Priority to CN201980017151.9A priority patent/CN111819293A/zh
Publication of WO2019172598A1 publication Critical patent/WO2019172598A1/fr
Priority to JP2021211759A priority patent/JP7300762B2/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Definitions

  • the present invention relates to Lactobacillus bacteria-derived nano-vesicles and uses thereof, and more specifically, to a method for diagnosing gastric cancer, kidney failure, dementia, or stroke using nano-vesicles derived from Lactobacillus bacteria and the above-mentioned vesicles.
  • a composition for preventing, ameliorating or treating a disease is provided.
  • the disease is characterized by chronic inflammation, and the occurrence of chronic inflammation is accompanied by abnormalities in immune function against external causative factors.
  • the immune response to the causative agent derived from bacteria is the Th17 immune response that secretes the interleukin (IL) -17 cytokine, and neutrophil inflammation caused by the Th17 immune response occurs when exposed to the bacterial cause.
  • Inflammatory mediators such as tumor necrosis factor-alpha (TNF- ⁇ ) play an important role in the development of inflammation.
  • IL-6 secreted by a bacterial causative agent has recently been reported to play an important role in the differentiation into Th17 cells, and to be involved in the pathogenesis of cardiovascular diseases and neuropsychiatric diseases.
  • microbiota refers to a microbial community including microbes, archaea and eukarya that exist in a given settlement, and the intestinal microbiota is important for human physiology. It plays a role and is known to greatly affect human health and disease through interaction with human cells.
  • Symbiotic bacteria and archaea which live in our bodies, secrete nanometer-sized vesicles to exchange information about genes and proteins to other cells.
  • the mucous membrane forms a physical protective film that particles larger than 200 nanometers (nm) in size can't pass through. If the bacteria are symbiotic bacteria, the mucosa cannot pass through the mucous membrane, but the bacteria-derived vesicles are 100 nanometers in size or less. It passes through epithelial cells through the mucous membrane and is absorbed by our body. The pathogenic bacteria-derived vesicles absorbed by our bodies have recently been found to play an important role in the pathogenesis of metabolic diseases such as diabetes and obesity.
  • Lactobacillus in bacteria is a Gram-positive bacteria that secrete a legacy, has been used in many bacteria are probiotics products belonging to the genus Lactobacillus.
  • probiotics products belonging to the genus Lactobacillus.
  • the present inventors earnestly researched to solve the above-mentioned problems.
  • metagenome analysis significantly reduced the contents of bacteria derived from Lactobacillus bacteria in samples derived from gastric cancer, kidney failure, dementia, and stroke patients compared to normal people.
  • the Lactobacillus bacteria-derived vesicles were isolated in vitro to evaluate the therapeutic efficacy, and as a result, the present invention was completed.
  • an object of the present invention is to provide an information providing method for the diagnosis of gastric cancer, kidney failure, dementia, or stroke.
  • Another object of the present invention is to provide a composition for preventing, improving or treating inflammatory diseases with an immune dysfunction including Lactobacillus-derived vesicles as an active ingredient.
  • the present invention provides a method for providing information for the diagnosis of gastric cancer, kidney failure, dementia, or stroke, comprising the following steps:
  • the present invention provides a method for diagnosing gastric cancer, kidney failure, dementia, or stroke, comprising the following steps:
  • the sample in step (a) may be blood.
  • the primer pair in step (b) may be a primer of SEQ ID NO: 1 and SEQ ID NO: 2.
  • the present invention comprises a bacterium derived from Lactobacillus genus as an active ingredient, accompanied by abnormal immune function It provides a pharmaceutical composition for preventing or treating inflammatory diseases.
  • the present invention provides a food composition for preventing or improving inflammatory diseases, including immune function abnormalities, including vesicles derived from Lactobacillus bacteria as an active ingredient.
  • the present invention provides a cosmetic composition for preventing or improving skin inflammatory diseases, comprising a vesicle derived from Lactobacillus bacteria as an active ingredient.
  • the present invention is a vesicle derived from the bacteria of the genus Lactobacillus, accompanied by abnormal immune function Provided for the prevention or treatment of inflammatory diseases.
  • the present invention comprises the step of administering to a subject a pharmaceutical composition comprising a Lactobacillus bacteria-derived vesicles as an active ingredient, accompanied by immune function
  • a pharmaceutical composition comprising a Lactobacillus bacteria-derived vesicles as an active ingredient, accompanied by immune function
  • the vesicles may have an average diameter of 10 to 200 nm.
  • the vesicles may be secreted naturally or artificially from bacteria of the genus Lactobacillus.
  • the Lactobacillus ( Lacotobacillus ) bacteria-derived vesicles are derived from Lactobacillus brevis ( Lacotobacillus brevis ) vesicles, Lactobacillus casei ( Lacotobacillus casei ) vesicles, Lactobacillus rhamnosus ( Lacotobacillus rhamnosus ) -derived vesicles And it may be one or more vesicles selected from the group consisting of Lacotobacillus sakei- derived vesicles.
  • the inflammatory disease may be one or more diseases selected from the group consisting of gastric cancer, kidney failure, dementia, and stroke.
  • the present inventors confirmed that the intestinal bacteria are not absorbed into the body, but when the bacteria-derived vesicles are absorbed into the body and distributed systemically, they are excreted in vitro through the kidneys, liver, and lungs. Derived vesicles metagenome analysis confirmed that Lactobacillus bacteria-derived vesicles present in gastric cancer, kidney failure, dementia, and stroke patient samples were significantly reduced compared to normal individuals.
  • the bacterium derived from Lactobacillus according to the present invention is a method for diagnosing gastric cancer, kidney failure, dementia, or stroke, and It is expected that the present invention may be usefully used in a composition for preventing, ameliorating or treating diseases.
  • Figure 1a is a picture of the distribution of bacteria and vesicles by time after oral administration of bacteria and bacteria-derived vesicles (EV) to the mouse
  • Figure 1b is 12 hours after oral administration
  • blood blood
  • kidney Figure shows the distribution of bacteria, vesicles and vesicles in the body, liver and various organs.
  • Figure 2 is a result of comparing the distribution of bacteria-derived vesicles of the genus Lactobacillus after the analysis of bacteria-derived vesicles metagenome present in gastric cancer patients and normal blood.
  • 3 is a result of comparing the distribution of bacteria-derived vesicles of the genus Lactobacillus after analyzing the bacteria-derived vesicles metagenome present in renal failure patients and normal blood.
  • Figure 5 is a result of comparing the distribution of bacteria-derived vesicles of the genus Lactobacillus after the analysis of bacteria-derived vesicles metagenome present in stroke patients and normal blood.
  • FIG. 6 shows Lactobacillus plantarum or Lactobacillus brevis (L. plantarum) before treatment of E. coli EV, a pathogenic vesicle, to evaluate the immunomodulatory and anti-inflammatory effects of Lactobacillus brevis-derived vesicles.
  • brevis -derived vesicles were pretreated to evaluate the effects of E. coli vesicles on secretion of inflammatory mediators IL-6 and TNF- ⁇ (PC: positive control; LP: Lactobacillus plantarum EVs; LB: Lactobacillus brevis EVs).
  • FIG. 7 shows Lactobacillus plantarum or Lactobacillus casei ( L. plantarum ) before treatment with Escherichia coli vesicles ( E. coli EV) to evaluate the immunomodulatory and anti-inflammatory effects of Lactobacillus cassia-derived vesicles .
  • Casei ) derived vesicles were pretreated to evaluate the effects on E. coli vesicles secrete IL-6 and TNF- ⁇ secretion (PC: positive control; LP: Lactobacillus plantarum EVs; LC: Lactobacillus casei EVs).
  • FIG. 8 shows Lactobacillus plantarum or Lactobacillus rhamnosus before treatment of Escherichia coli vesicles (E. coli EV) to evaluate the immunomodulatory and anti-inflammatory effects of Lactobacillus rhamnosus-derived vesicles.
  • E. coli EV Escherichia coli vesicles
  • L. rhamnosus vesicles were pretreated to evaluate the effect of E. coli vesicles on the secretion of inflammatory mediators IL-6 and TNF- ⁇
  • PC positive control
  • LP Lactobacillus plantarum EVs
  • LR Lactobacillus rhamnosus EVs
  • E. coli EV pathogenic E. coli vesicles
  • Lactobacillus Planta room L. plantarum
  • Lactobacillus four K before the treatment L. sakei
  • PC positive control
  • LP Lactobacillus plantarum EVs
  • LS Lactobacillus sakei EVs
  • the present invention relates to vesicles derived from the genus Lactobacillus and uses thereof.
  • the present inventors have found that the vesicle-derived bacterium from Lactobacillus is significantly reduced in gastric cancer, renal failure, dementia, and stroke patients compared to normal people, thereby confirming that the disease can be diagnosed.
  • the vesicles can be used as a composition for the prevention or treatment of the disease.
  • the present invention provides an information providing method for diagnosing gastric cancer, kidney failure, dementia, or stroke, comprising the following steps:
  • diagnosis in the broad sense means to determine the actual condition of the patient's disease in all aspects. The content of the judgment is the name of the disease, the etiology, the type of disease, the seriousness, the detailed mode of the condition, the presence or absence of complications, and the prognosis. Diagnosis in the present invention is to determine the onset of gastric cancer, renal failure, dementia, and stroke and the level of disease.
  • the term "metagenome” used in the present invention also referred to as "gunoelectric”, refers to the sum total of the genome including all viruses, bacteria, fungi, etc. in an isolated area such as soil, animal intestine, mainly culture It is used as a concept of genome explaining the identification of many microorganisms at once using sequencer to analyze microorganisms that are not.
  • the metagenome does not refer to one genome or genome, but to a kind of mixed dielectric as the genome of all species of one environmental unit. This is a term from the point of view of defining a species in the course of the evolution of biology in terms of functional species as well as various species that interact with each other to create a complete species.
  • rapid sequencing is used to analyze all DNA and RNA, regardless of species, to identify all species in one environment, and to identify interactions and metabolism.
  • the sample may be blood, but is not limited thereto.
  • the present invention provides a composition for the prevention, treatment or improvement of inflammatory diseases, including gastric cancer, kidney failure, dementia, stroke or skin inflammatory diseases, including vesicles derived from Lactobacillus bacteria as an active ingredient.
  • the composition comprises a food composition, a cosmetic composition and a pharmaceutical composition, in the present invention, the food composition comprises a nutraceutical composition.
  • the composition of the present invention may be a formulation of an oral nebulizer or inhalant.
  • vesicle refers to a structure of nanoscale membranes secreted by various bacteria.
  • vesicles derived from gram-positive bacteria such as Lactobacillus have peptidoglycan, lipoteichoic acid, and various low molecular weight compounds in the vesicles. have.
  • the nano vesicles or vesicles are naturally secreted or artificially produced by Lactobacillus bacteria, and have an average diameter of 10 to 200 nm.
  • the vesicles are centrifuged, ultra-fast centrifugation, high pressure treatment, extrusion, sonication, cell lysis, homogenization, freeze-thaw, electroporation, mechanical degradation, chemical treatment, filtration by a filter containing bacteria of the genus Lactobacillus. It can be separated using one or more methods selected from the group consisting of, gel filtration chromatography, pre-flow electrophoresis, and capillary electrophoresis. In addition, it may further include a process for washing to remove impurities, concentration of the obtained vesicles and the like.
  • prevention means any action that inhibits or delays the development of an inflammatory disease, including gastric cancer, kidney failure, dementia, stroke, and / or skin inflammatory diseases, by administration of a composition according to the present invention. Means.
  • treatment means any improvement or beneficial alteration of symptoms for inflammatory diseases, including gastric cancer, kidney failure, dementia, stroke, and / or skin inflammatory diseases, by administration of a composition according to the invention. It means an act.
  • the term “improvement” means any action that at least reduces the parameters associated with the condition being treated, for example, the extent of symptoms.
  • Inflammatory diseases in the present invention are caused by a series of biological reactions caused by a direct response to the immune media's humoral mediator or by stimulating a local or systemic effector system. It may be a stroke or skin inflammatory disease, and may be accompanied by abnormal immune function, but is not limited thereto.
  • the pharmaceutical composition according to the invention may comprise a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carriers are conventionally used in the preparation, and include, but are not limited to, saline solution, sterile water, Ringer's solution, buffered saline, cyclodextrin, dextrose solution, maltodextrin solution, glycerol, ethanol, liposomes, and the like. If necessary, other conventional additives such as antioxidants and buffers may be further included.
  • diluents, dispersants, surfactants, binders, lubricants and the like may be additionally added to formulate injectable formulations, pills, capsules, granules, or tablets such as aqueous solutions, suspensions, emulsions and the like.
  • Suitable pharmaceutically acceptable carriers and formulations can be preferably formulated according to the individual components using methods disclosed in Remington's literature.
  • the pharmaceutical composition of the present invention is not particularly limited in formulation, but may be formulated as an injection, inhalant, external preparation for skin, oral ingestion, and the like.
  • the pharmaceutical composition of the present invention can be administered orally or parenterally (eg, applied intravenously, subcutaneously, skin, nasal, airways) according to the desired method, and the dosage is determined by the condition and weight of the patient, disease Depending on the degree, drug form, route of administration, and time, it may be appropriately selected by those skilled in the art.
  • the pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount.
  • the pharmaceutically effective amount means an amount sufficient to treat the disease at a reasonable benefit / risk ratio applicable to the medical treatment, and the effective dose level refers to the type of disease, the severity, the activity of the drug and the drug. Sensitivity, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of drugs, and other factors well known in the medical arts.
  • the composition according to the present invention may be administered as a separate therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, which can be easily determined by those skilled in the art.
  • the effective amount of the pharmaceutical composition according to the present invention may vary depending on the age, sex and weight of the patient, and generally 0.001 to 150 mg, preferably 0.01 to 100 mg daily or every other day, per kg of body weight Or divided into 1 to 3 times a day.
  • the dosage may be increased or decreased depending on the route of administration, the severity of obesity, sex, weight, age, etc., and the above dosage does not limit the scope of the present invention in any way.
  • the food composition of the present invention includes a nutraceutical composition.
  • the food composition according to the present invention may be used as it is, or may be used in combination with other foods or food ingredients, or may be appropriately used according to conventional methods.
  • the mixing amount of the active ingredient can be suitably determined according to the purpose of use (prevention or improvement).
  • the compositions of the invention are added in amounts of up to 15% by weight, preferably up to 10% by weight relative to the raw materials.
  • the amount may be below the above range.
  • the food composition of the present invention in addition to containing the active ingredient as an essential ingredient in the indicated ratio, there are no particular restrictions on other ingredients, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks.
  • natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • natural flavoring agents such as, tauumatin, stevia extract, for example, rebaudioside A, glycyrrhizin, etc.
  • synthetic flavoring agents sacharin, aspartame, etc.
  • the proportion of the natural carbohydrate can be appropriately determined by the choice of those skilled in the art.
  • the food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and Salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like.
  • these components can be used independently or in combination.
  • the proportion of such additives may also be appropriately selected by those skilled in the art.
  • the cosmetic composition of the present invention may include not only vesicles derived from Lactobacillus bacteria, but also components commonly used in cosmetic compositions, for example, such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and perfumes. Adjuvants, and carriers.
  • composition of the present invention may be used in addition to the vesicles derived from Lactobacillus bacteria, organic sunscreens that have been conventionally used insofar as it does not impair the skin protection effect by reacting with the vesicles derived from Lactobacillus bacteria.
  • organic sunscreen examples include glyceryl pava, drometrizole trisiloxane, drometrizole, digaloyltrioleate, disodium phenyldibenzimidazole tetrasulfonate, diethylhexyl butamidotriazone, diethylamino Hydroxybenzoylhexylbenzoate, die-methoxycinnamate, a mixture of lowson and dihydroxyacetone, methylenebis-benzotriazolyltetramethylbutylphenol, 4-methylbenzylidene camphor, menthyl anthranilate, benzophenone -3 (oxybenzone), benzophenone-4, benzophenone-8 (dioxyphenbenzone), butylmethoxydibenzoylmethane, bisethylhexyloxyphenol methoxyphenyltriazine, synoxate, ethyldihydroxypropylpava, Oct
  • Examples of products to which the cosmetic composition of the present invention may be added include, for example, cosmetics such as astringent cosmetics, soft cosmetics, nourishing cosmetics, various creams, essences, packs, foundations, and the like, cleansing agents, soaps, treatments, and essences.
  • Specific formulations of the cosmetic composition of the present invention include skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, essence, nutrition essence, pack, Formulations such as soaps, shampoos, cleansing foams, cleansing lotions, cleansing creams, body lotions, body cleansers, emulsions, lipsticks, makeup bases, foundations, press powders, loose powders, eye shadows and the like.
  • the bacteria and bacteria-derived vesicles orally administered to observe the body absorption, distribution, and excretion of the bacteria and vesicles in the body in the case of bacteria is not absorbed through the intestinal membrane, the vesicles are administered 5 It was confirmed that it was absorbed within minutes and distributed systemically and excreted through the kidney, liver, and the like (see Example 1).
  • metagenome analysis was performed in gastric cancer, kidney failure, dementia, and stroke patients and normal blood. As a result, it was confirmed that Lactobacillus bacteria-derived vesicles were significantly reduced in the blood of stomach cancer, kidney failure, dementia, and stroke patients compared to normal blood (see Examples 3 to 6).
  • the immunomodulatory and anti-inflammatory effects of Lactobacillus brevis strain-derived vesicles were evaluated, and Lactobacillus plantarum or Lactobacillus brevis-derived vesicles of various concentrations were treated before treating the pathogenic vesicle-derived E. coli-derived vesicles. After treatment with macrophages, the secretion of inflammatory mediators was evaluated. As a result, it was confirmed that the lactobacillus brevis-derived vesicles by E. coli-derived vesicles suppressed the vesicles derived from Lactobacillus plantarum more efficiently. See examples 7 and 8).
  • the immunomodulatory and anti-inflammatory effects of the vesicles derived from Lactobacillus casei strains were evaluated, and treated with Escherichia coli-derived vesicles, which are pathogenic vesicles, before the Lactobacillus plantarum or various concentrations of Lactobacillus casei-derived vesicles.
  • Escherichia coli-derived vesicles which are pathogenic vesicles, before the Lactobacillus plantarum or various concentrations of Lactobacillus casei-derived vesicles.
  • the secretion of inflammatory mediators was evaluated, and it was confirmed that the TNF- ⁇ secretion by E. coli-derived vesicles was suppressed more efficiently than the Lactobacillus plantarum-derived vesicles (Lactobacillus plantarum-derived vesicles). See examples 7 and 9).
  • the immunomodulatory and anti-inflammatory effects of Lactobacillus rhamnosus strain-derived vesicles were evaluated, and Lactobacillus plantarum or various concentrations of Lactobacillus rhamnosus before treatment with Escherichia coli-derived vesicles, which are pathogenic vesicles.
  • E. coli-derived vesicles After treating the derived vesicles with macrophages and evaluating the secretion of inflammatory mediators, it was confirmed that the TNF- ⁇ secretion by E. coli-derived vesicles suppressed Lactobacillus rhamnosus-derived vesicles more efficiently than Lactobacillus plantarum-derived vesicles. (See Examples 7 and 10).
  • the immunomodulatory and anti-inflammatory effects of the vesicles derived from Lactobacillus Sakei strains were evaluated, and Lactobacillus plantarum or various concentrations of Lactobacillus sakei before treatment of Escherichia coli-derived vesicles, which are pathogenic vesicles
  • Lactobacillus plantarum or various concentrations of Lactobacillus sakei before treatment of Escherichia coli-derived vesicles, which are pathogenic vesicles
  • the LN- ⁇ secretion by E. coli-derived vesicles effectively inhibited Lactobacillus plant-derived vesicles compared with Lactobacillus plantarum-derived vesicles. (See Examples 7 and 11).
  • Example 1 Analysis of absorption, distribution, and excretion of intestinal bacteria and bacterial-derived vesicles
  • DNA extracted by the above method was amplified using the above 16S rDNA primers, followed by sequencing (Illumina MiSeq sequencer), and the results were outputted in a Standard Flowgram Format (SFF) file, using GS FLX software (v2.9).
  • SFF Standard Flowgram Format
  • GS FLX Standard Flowgram Format
  • OTU operational taxonomy unit
  • clustering is performed according to sequence similarity using UCLUST and USEARCH, genus 94%, family 90%, order 85%, class 80%, phylum 75% sequence similarity
  • Clustering is based on the phylum, class, order, family, and genus levels of each OTU, and BLASTN and GreenGenes' 16S RNA sequence database (108,453 sequences) is used to identify bacteria with greater than 97% sequence similarity at the genus level.
  • Was profiled QIIME).
  • Example 2 the blood of 66 gastric cancer patients and 198 normal blood patients whose age and sex were matched were extracted from the vesicles in the blood and subjected to metagenomic analysis, and then derived from the bacteria of the genus Lactobacillus. The distribution of vesicles was evaluated. As a result, it was confirmed that the vesicle-derived bacteria of the genus Lactobacillus significantly decreased in the blood of gastric cancer patients compared to the normal blood (see Table 2 and Figure 2).
  • Example 2 the blood of 21 renal convertors and 19 normal blood patients whose age and sex were matched were extracted from the vesicles present in the blood and subjected to metagenomic analysis. The distribution of vesicles was evaluated. As a result, it was confirmed that Lactobacillus bacteria-derived vesicles were significantly reduced in the blood of the renal converter compared to normal blood (see Table 3 and FIG. 3).
  • Example 2 the blood of 115 stroke patients and 109 normal blood patients whose age and sex were matched were extracted from the vesicles present in the blood and subjected to metagenomic analysis, followed by derivation of bacteria of the genus Lactobacillus. The distribution of vesicles was evaluated. As a result, it was confirmed that the bacteria-derived Lactobacillus-derived vesicles significantly reduced in the blood of stroke patients compared to normal blood (see Table 5 and FIG. 5).
  • Lactobacillus brevis Lactobacillus casei , Lactobacilus Lactobacilus rhamnosus
  • Lactobacillus sakei strains were isolated from the environmental samples, cultured, and then their vesicles were isolated and characterized.
  • Each Lactobacillus strain was cultured in de Man-Rogosa and Sharpe (MRS) medium until absorbance (OD 600 ) was 1.0 to 1.5 at 37 ° C aerobic conditions, and then sub-cultured to Luria-Bertani (LB) medium. It was. Then, the medium containing the strain was recovered, centrifuged at 10,000 g, 4 ° C. for 20 minutes to remove the strain, and filtered through a 0.22 ⁇ m filter.
  • MRS de Man-Rogosa and Sharpe
  • the filtered supernatant was concentrated to 50 ml volume by microfiltration using a MasterFlex pump system (Cole-Parmer, US) with a 100 kDa Pellicon 2 Cassette filter membrane (Merck Millipore, US). The concentrated supernatant was once again filtered through a 0.22 ⁇ m filter. Thereafter, the protein was quantified using the BCA assay, and the following experiment was performed on the obtained vesicles.
  • lactobacillus brevis-derived vesicles In order to evaluate the immunomodulatory and anti-inflammatory effects of Lactobacillus brevis-derived vesicles, lactobacillus brevis-derived vesicles of various concentrations (0.1, 1, 10 ⁇ g / ml) were pretreated in macrophage lines for 12 hours, followed by Escherichia coli, a pathogenic vesicle. After 12 hours of treatment with vesicles, the secretion of inflammatory cytokines was measured by ELISA. To perform ELISA, the capture antibody was diluted in phosphate buffered saline (PBS), 50 ⁇ l aliquots were applied to 96 well polystyrene plates at a working concentration, and then reacted at 4 ° C. overnight. .
  • PBS phosphate buffered saline
  • PBST PBS containing 0.05% tween-20
  • RD PBS containing 1% BSA
  • 50 ⁇ l of the standard was adjusted according to the concentration, and reacted at room temperature for 2 hours.
  • the detection antibody was diluted in RD, 50 ⁇ l was dispensed to the working concentration for 2 hours at room temperature, washed three times with 100 ⁇ l of PBST, and then Strpetavidin-HRP. (R & D system, USA) was diluted 1/40 in RD, 50 ⁇ l was dispensed and reacted at room temperature for 20 minutes.
  • TMB substrate (SurModics, USA) is dispensed, and when the color development progresses after 5 to 20 minutes, 50 ⁇ l of 1 M sulfuric acid solution is stopped to stop the reaction. Absorbance was measured at 450 nm using a SpectraMax M3 microplate reader (Molecular Devices, USA).
  • Lactobacillus casei-derived vesicles of various concentrations (0.1, 1, 10 ⁇ g / ml) were pretreated in macrophage lines for 12 hours, followed by Escherichia coli, a pathogenic vesicle. After 12 hours of treatment with vesicles, the secretion of inflammatory cytokines was measured by ELISA. As a result, when the Lactobacillus casei-derived vesicles were pretreated, it was confirmed that the secretion of IL-6 and TNF- ⁇ by E. coli-derived vesicles was significantly inhibited (see FIG. 7).
  • Lactobacillus casei-derived vesicles pretreated it was confirmed that the effect of inhibiting TNF- ⁇ secretion is significantly more effective than Lactobacillus plantarum ( Lactobacillus plantarum ), which is a useful microorganism control (see Fig. 7b).
  • Lactobacillus rhamnosus-derived vesicles In order to evaluate the immunomodulatory and anti-inflammatory effects of Lactobacillus rhamnosus-derived vesicles, Lactobacillus rhamnosus-derived vesicles of various concentrations (0.1, 1, 10 ⁇ g / ml) were pretreated in macrophage lines for 12 hours, followed by pathogenic vesicles. The secretion of inflammatory cytokines was measured by ELISA 12 hours after treatment with 1 ⁇ g / ml E. coli-derived vesicles. As a result, as shown in Figure 8, when the Lactobacillus rhamnosus-derived vesicles pretreated, it was confirmed that the secretion of IL-6 and TNF- ⁇ by E.
  • Lactobacillus sakei-derived vesicles In order to evaluate the immunomodulatory and anti-inflammatory effects of Lactobacillus sakei-derived vesicles, Lactobacillus sakei-derived vesicles of various concentrations (0.1, 1, 10 ⁇ g / ml) were pretreated in macrophage lines for 12 hours and then pathogenic vesicles The secretion of inflammatory cytokines was measured by ELISA 12 hours after treatment with 1 ⁇ g / ml E. coli-derived vesicles. As a result, when pre-treatment of the Lactobacillus Sakei-derived vesicles as shown in Figure 9, it was confirmed that the secretion of IL-6 and TNF- ⁇ by E. coli-derived vesicles is significantly suppressed.
  • Lactobacillus bacteria-derived vesicles according to the present invention can be used as a diagnostic method for gastric cancer, renal failure, dementia or stroke, as well as a composition for the prevention, improvement or treatment of the above diseases, so as to be useful in related medical, cosmetic and food industries It is expected to be available.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des vésicules dérivées de bactéries Lactobacillus sp. et une de leurs utilisations. Les présents inventeurs ont confirmé par expérimentation que : comparativement à celles d'une personne en bonne santé, les vésicules sont significativement réduites dans les échantillons provenant de patients souffrant de cancer de l'estomac, insuffisance rénale, démence et accident vasculaire cérébral; et que les vésicules inhibaient la sécrétion des médiateurs inflammatoires par des vésicules pathogènes. Ainsi, les vésicules dérivées de bactéries Lactobacillus sp., selon la présente invention, peuvent être utilement employées dans le but de développer : une méthode de diagnostic du cancer de l'estomac, de l'insuffisance rénale, de la démence et de l'accident vasculaire cérébral; et une composition pour prévenir, améliorer ou traiter les maladies inflammatoires, dont lesdites maladies, s'accompagnant d'une dysfonction immunitaire.
PCT/KR2019/002500 2018-03-05 2019-03-05 Nanovésicules dérivées de bactéries lactobacillus sp., et leur utilisation WO2019172598A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP19764446.1A EP3763830A4 (fr) 2018-03-05 2019-03-05 Nanovésicules dérivées de bactéries lactobacillus sp., et leur utilisation
JP2020546410A JP2021516054A (ja) 2018-03-05 2019-03-05 ラクトバチルス属細菌由来のナノ小胞及びその用途
US16/978,597 US20210030821A1 (en) 2018-03-05 2019-03-05 Nanovesicles derived from lactobacillus sp. bacteria, and use thereof
CN201980017151.9A CN111819293A (zh) 2018-03-05 2019-03-05 来源于乳杆菌种细菌的纳米囊泡及其用途
JP2021211759A JP7300762B2 (ja) 2018-03-05 2021-12-27 ラクトバチルス属細菌由来のナノ小胞及びその用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2018-0026039 2018-03-05
KR20180026039 2018-03-05
KR10-2019-0024891 2019-03-04
KR1020190024891A KR102101692B1 (ko) 2018-03-05 2019-03-04 락토바실러스 속 세균 유래 나노소포 및 이의 용도

Publications (1)

Publication Number Publication Date
WO2019172598A1 true WO2019172598A1 (fr) 2019-09-12

Family

ID=67846588

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/002500 WO2019172598A1 (fr) 2018-03-05 2019-03-05 Nanovésicules dérivées de bactéries lactobacillus sp., et leur utilisation

Country Status (1)

Country Link
WO (1) WO2019172598A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112011607A (zh) * 2020-09-19 2020-12-01 河北医科大学第二医院 源于肠道与脑卒中诊断和治疗效果相关的菌群及其应用
JP2023513507A (ja) * 2020-02-05 2023-03-31 エイチイエム ファーマ インコーポレイテッド 新規なラクトバチルスサケイｈｅｍ２２４菌株、及び上記菌株又はその培養物を含む炎症又は喘息の治療用組成物
JP7449520B2 (ja) 2020-03-04 2024-03-14 エムディー ヘルスケア インコーポレイテッド ラクトバチルス属細菌由来細胞外小胞を有効成分として含む幹細胞機能調節用組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110025603A (ko) * 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 세균유래 세포밖 소포체 및 이의 용도
KR20160073157A (ko) * 2014-12-16 2016-06-24 이화여자대학교 산학협력단 세균 유래의 나노소포체를 이용한 세균성 감염질환 원인균 동정방법
KR20160110232A (ko) * 2015-03-11 2016-09-21 주식회사 엠디헬스케어 유산균 유래 세포밖 소포체를 유효성분으로 포함하는 염증질환의 예방 또는 치료용 조성물
KR101833348B1 (ko) * 2016-12-26 2018-03-02 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 유방암 진단방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110025603A (ko) * 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 세균유래 세포밖 소포체 및 이의 용도
KR20160073157A (ko) * 2014-12-16 2016-06-24 이화여자대학교 산학협력단 세균 유래의 나노소포체를 이용한 세균성 감염질환 원인균 동정방법
KR20160110232A (ko) * 2015-03-11 2016-09-21 주식회사 엠디헬스케어 유산균 유래 세포밖 소포체를 유효성분으로 포함하는 염증질환의 예방 또는 치료용 조성물
KR101833348B1 (ko) * 2016-12-26 2018-03-02 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 유방암 진단방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PARK, J.Y. ET AL.: "Metagenome Analysis of Bodily Microbiota in a Mouse Model of Alzheimer Disease Using Bacteria-derived Membrane Vesicles in Blood", EXP. NEUROBIOL., vol. 26, no. 6, December 2017 (2017-12-01), pages 369 - 379, XP055547921, doi:10.5607/en.2017.26.6.369 *
See also references of EP3763830A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023513507A (ja) * 2020-02-05 2023-03-31 エイチイエム ファーマ インコーポレイテッド 新規なラクトバチルスサケイｈｅｍ２２４菌株、及び上記菌株又はその培養物を含む炎症又は喘息の治療用組成物
JP7432745B2 (ja) 2020-02-05 2024-02-16 エイチイエム ファーマ インコーポレイテッド 新規なラクトバチルスサケイｈｅｍ２２４菌株、及び上記菌株又はその培養物を含む炎症又は喘息の治療用組成物
JP7449520B2 (ja) 2020-03-04 2024-03-14 エムディー ヘルスケア インコーポレイテッド ラクトバチルス属細菌由来細胞外小胞を有効成分として含む幹細胞機能調節用組成物
CN112011607A (zh) * 2020-09-19 2020-12-01 河北医科大学第二医院 源于肠道与脑卒中诊断和治疗效果相关的菌群及其应用

Similar Documents

Publication Publication Date Title
KR102101692B1 (ko) 락토바실러스 속 세균 유래 나노소포 및 이의 용도
KR102085787B1 (ko) 바실러스 속 세균 유래 나노소포 및 이의 용도
KR102087105B1 (ko) 큐프리아비더스 속 세균 유래 나노소포 및 이의 용도
KR102011375B1 (ko) 프로테우스 속 세균 유래 나노소포 및 이의 용도
WO2018030732A1 (fr) Nanovésicules dérivées de bactéries du genre bacillus et leur utilisation
KR102118197B1 (ko) 마이크로코커스 속 세균 유래 나노소포 및 이의 용도
KR102463399B1 (ko) 락토코커스 속 세균 유래 나노소포 및 이의 용도
WO2019172598A1 (fr) Nanovésicules dérivées de bactéries lactobacillus sp., et leur utilisation
KR20190106723A (ko) 코프로코커스 속 세균 유래 나노소포 및 이의 용도
KR20190103965A (ko) 스트렙토코커스 속 세균 유래 나노소포 및 이의 용도
WO2019156449A1 (fr) Nanovésicules dérivées de bactéries du genre lactococcus et leur utilisation
KR20190106722A (ko) 콜린셀라 속 세균 유래 나노소포 및 이의 용도
WO2020145661A1 (fr) Nanovésicules dérivées de bactéries du genre propionibacterium et leur utilisation
WO2019172604A1 (fr) Nanovésicules issues de bactéries collinsella sp., et leur utilisation
WO2019164197A1 (fr) Nano-vésicules dérivées de bactéries catenibacterium et utilisation associée
KR102142327B1 (ko) 아시네토박터 속 세균 유래 나노소포 및 이의 용도
KR20190094109A (ko) 비피도박테리움 속 세균 유래 나노소포 및 이의 용도
WO2019168327A1 (fr) Nanovésicules issues de bactéries micrococcus et leur utilisation
WO2019172607A1 (fr) Nanovésicules issues de bactéries coprococcus sp., et leur utilisation
WO2019168331A1 (fr) Nanovésicules issues de bactéries pseudomonas, et leur utilisation
WO2019168329A1 (fr) Nanovésicules issues de bactéries acinetobacter et utilisation associée
WO2019168328A1 (fr) Nanovésicules dérivées de bactéries rhizobium sp., et leur utilisation
WO2019151825A1 (fr) Nanovésicules issues de bactéries bifidobacterium, et leur utilisation
WO2019168330A1 (fr) Nanovésicules dérivées de bactéries streptococcus sp., et leur utilisation
WO2020122449A1 (fr) Nano-vésicule dérivée de corynebacterium sp. bactéries et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19764446

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020546410

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019764446

Country of ref document: EP

Effective date: 20201005